PMDA Japan Drug Approval: Process, Timelines, and Submission Requirements

PMDA Japan Drug Approval: Process, Timelines, and Submission Requirements

Key Takeaways

Japan's Drug Regulatory System: PMDA and MHLW

Organizational Structure

Japan's pharmaceutical regulatory system has two key entities:

PMDA was established in 2004 by merging the review functions previously dispersed across multiple organizations. It operates under the MHLW but functions as an independent administrative agency for review purposes.

PMDA's key functions:

• Pre-application consultations with sponsors
• Scientific review of marketing applications (quality, non-clinical, clinical)
• GMP compliance inspections (conformity assessment)
• Post-market safety measures and adverse event monitoring
• Relief services for drug-related injuries

MHLW's key functions:

• Issues marketing approval based on PMDA review
• Sets pharmaceutical policies and regulatory frameworks
• Publishes the Japanese Pharmacopoeia (JP)
• Establishes pricing and reimbursement through the National Health Insurance (NHI) system

Legal Framework

The primary law governing drug approval in Japan is the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (commonly called the PMD Act, formerly the Pharmaceutical Affairs Law). The PMD Act was substantially revised in 2013 and again in 2019.

Key regulatory provisions:

• Article 14: Marketing approval requirements for drugs
• Article 14-3: Provisions for conditional and time-limited approvals
• Article 14-4: Re-examination system (post-approval monitoring period)
• Article 14-6: Re-evaluation system (periodic benefit-risk reassessment)

Submission Types in Japan

Marketing Authorization Applications

Marketing Authorization Holder (MAH)

In Japan, the Marketing Authorization Holder (MAH) must be a legal entity with a physical presence in Japan. Foreign sponsors cannot directly hold a marketing authorization. Options for foreign companies include:

• Establishing a Japanese subsidiary
• Partnering with a Japanese pharmaceutical company as the MAH
• Using a contract MAH (though the MAH retains full regulatory responsibility)

The MAH system was revised in 2005 to separate manufacturing from marketing authorization, allowing companies without manufacturing facilities in Japan to hold marketing authorizations through a third-party manufacturer arrangement.

The J-NDA Process: From Filing to Approval

Pre-Application: The PMDA Consultation System

Japan's regulatory process is distinguished by its structured consultation system, which allows sponsors to engage with PMDA at defined stages during drug development. These consultations are formal, fee-based meetings that produce official records.

Types of PMDA Consultations:

Key characteristics of PMDA consultations:

• Consultations are fee-based under PMDA's published user-fee schedules
• PMDA issues a formal consultation record (Sodan Kiroku) that is shared with the sponsor
• Consultation records inform the subsequent review process
• While consultation outcomes are advisory, reviewers will refer to them during the application review

The consultation system is one of PMDA's most distinctive features. Unlike FDA pre-IND or Type B meetings (which are less formalized), PMDA consultations are highly structured with specific deliverables and follow-up mechanisms.

Application Filing

The J-NDA is filed with PMDA, which serves as the receiving authority for all marketing applications. Filing requirements:

• Application must follow PMDA's electronic submission specifications and Japan-specific regional content requirements
• JP Module 1 must contain Japan-specific administrative documents
• Application fee must be paid
• All documents must be in Japanese or accompanied by Japanese translations
• The applicant must be a legal entity in Japan (or have a Japanese MAH partner)

PMDA Review Process

PMDA conducts a multi-phase review:

Phase 1: Administrative Review (approximately 2 weeks)

• Verify application completeness
• Confirm fee payment
• Assign review team

Phase 2: Expert Discussion and Outline of Review

• Review team conducts initial assessment
• Identifies key issues for detailed evaluation
• Prepares review outline

Phase 3: Detailed Review (main review period)

• Quality (CMC) review
• Non-clinical review
• Clinical review (efficacy and safety)
• Biostatistics review
• Queries issued to applicant as needed

During review, PMDA issues queries (Shitsumon) to the sponsor, who must respond within specified timeframes. Multiple rounds of queries are common.

Phase 4: Expert Committee Discussion

• After the review team completes its assessment, the application goes to an Expert Committee (Senmonin Kaigi)
• The Expert Committee includes external experts and provides peer review of the PMDA review team's conclusions
• The Expert Committee may request additional data or analysis

Phase 5: PMDA Review Report

• PMDA prepares a Review Report (Shinsa Houkokusho) summarizing the review findings and conclusions
• The Review Report is submitted to MHLW with PMDA's recommendation

MHLW Approval

After receiving PMDA's Review Report, MHLW refers the application to the Pharmaceutical Affairs and Food Sanitation Council (PAFSC), which is an advisory body to the Minister. The PAFSC reviews the PMDA assessment and provides a recommendation.

The Minister of MHLW then issues the formal marketing approval (Shonin).

GMP Inspection (Conformity Assessment)

In parallel with the scientific review, PMDA (or prefectural government for domestic manufacturers) conducts GMP inspections of manufacturing sites.

PMDA inspects foreign manufacturing sites that produce drug substance or drug product for the Japanese market. These inspections are separate from FDA or EMA inspections and follow Japan-specific GMP standards (based on the Ministerial Ordinance on Standards for Manufacturing Control and Quality Control, often called J-GMP).

The GMP conformity assessment must be completed before marketing approval can be issued. GMP certificates are valid for 5 years.

eCTD Requirements: JP Module 1

Japan mandated eCTD format for all new drug applications. The eCTD follows the ICH CTD structure with Japan-specific Module 1 content.

JP Module 1 Structure

Japanese Package Insert (Tenpu Bunsho)

The Japanese Package Insert is Japan's prescribing information document. It follows a format prescribed by MHLW/PMDA that differs from both the US Prescribing Information and the EU SmPC.

Key characteristics:

• Must be written in Japanese
• Format follows the MHLW notification on package insert format
• Includes warnings, contraindications, composition, indications, dosage, adverse reactions, pharmacology, and other sections in a Japan-specific order
• An Interview Form (IF) provides additional detailed information not included in the Package Insert

Language Requirements

All Module 1 documents must be in Japanese. For Modules 2-5, PMDA accepts English-language documents with Japanese translations of key sections (summaries, key study reports). However, translations must be accurate and complete. PMDA reviewers generally have English reading capability, but official communications and regulatory documents must be in Japanese.

Japan-Specific Data Requirements

Bridging Studies (ICH E5)

Japan was instrumental in developing the ICH E5 guideline ("Ethnic Factors in the Acceptability of Foreign Clinical Data"), which establishes the framework for using foreign clinical data in Japanese regulatory submissions.

The bridging concept:

When pivotal clinical trials are conducted outside Japan, the sponsor may need to conduct a bridging study in Japanese patients to demonstrate that foreign clinical data can be extrapolated to the Japanese population.

When bridging studies are required:

Types of bridging approaches:

• Full bridging study: Pharmacokinetic and/or pharmacodynamic study in Japanese subjects demonstrating similarity to foreign data
• Partial extrapolation: Some Japanese clinical data plus foreign data, with pharmacokinetic comparison
• Complete extrapolation: No Japanese study required if ethnic sensitivity is low and foreign data are considered applicable (rare for novel drugs)

PMDA's Clinical Data Package Consultation is the appropriate venue to discuss bridging strategy before conducting studies.

Japanese Pharmacopoeia (JP) Compliance

Drug substances and products must comply with the Japanese Pharmacopoeia (JP) monographs where applicable. The JP is published by MHLW and is legally binding. Key considerations:

• If a JP monograph exists for the drug substance, specifications must meet JP requirements
• General tests and methods must follow JP procedures
• Excipients must meet JP or equivalent pharmacopeial standards
• The current edition is the 18th Edition of the Japanese Pharmacopoeia (JP18), effective 2021

Japanese Stability Data

PMDA requires stability data generated under ICH Q1A conditions, but with attention to Japanese-specific considerations:

• Climatic Zone II conditions (25 degrees C / 60% RH for long-term, 40 degrees C / 75% RH for accelerated) apply for Japan
• Photostability testing per ICH Q1B is required
• Stability data supporting the proposed shelf life must be available at the time of J-NDA filing

Review Timelines

Standard Review Timelines

PMDA publishes actual review times annually. Sponsors should rely on PMDA's current published targets and annual performance materials rather than using a single generic elapsed-time estimate for every application.

Note: The total time from filing to commercial availability includes additional time for:

• NHI price listing and reimbursement procedures after approval
• GMP conformity assessment (conducted in parallel with review but may extend if site issues arise)

Review Timeline Components

Expedited Pathways in Japan

SAKIGAKE Designation

SAKIGAKE (Pioneer) designation was introduced in 2015 and incorporated into the PMD Act in 2019. It is designed to promote drugs first developed and applied for in Japan.

Eligibility criteria:

• The drug treats a serious disease with no adequate treatment or offers a significant advantage over existing treatments
• The drug is intended to be first submitted in Japan (global first application)
• Early development activities were conducted in Japan

Benefits of SAKIGAKE designation:

• Priority consultation with PMDA (pre-application support)
• Priority review (target reduced to approximately 6 months)
• Concurrent review with regulatory advice (pre-application evaluation)
• Extension of re-examination period to up to 10 years (vs. standard 8 years for NCEs)

Important note: SAKIGAKE was originally designed to encourage "Japan-first" development. The 2019 PMD Act revision expanded the scope, but the Japan-first element remains a key criterion.

Conditional Early Approval System

Japan introduced a conditional early approval system in 2017 (and formally codified in the 2019 PMD Act revision) for drugs that treat serious conditions where confirmatory trial data are not yet complete.

Eligibility:

• Serious disease with high medical need
• Adequate confirmatory trial data not available at the time of application
• Drug shows efficacy based on exploratory trial or surrogate endpoint data
• Benefits outweigh risks based on available data

Conditions:

• Marketing authorization is time-limited (typically for a defined period)
• Sponsor must conduct post-market studies to confirm efficacy and safety
• Distribution may be restricted to specified medical institutions
• Authorization may be withdrawn if confirmatory data are unfavorable

This pathway is conceptually similar to FDA's Accelerated Approval and Health Canada's NOC/c but has a formal time-limited authorization mechanism that differs from both.

Orphan Drug Designation (Japan)

MHLW grants orphan drug designation for drugs targeting diseases affecting fewer than 50,000 patients in Japan and for which adequate treatments do not exist.

Benefits:

• Priority review (9-month target, same as standard priority review)
• PMDA consultation fee reductions
• Tax incentives for development costs
• Re-examination period extension (up to 10 years)
• Subsidies for clinical trial costs from AMED (Japan Agency for Medical Research and Development)

Priority Review

Independent of SAKIGAKE, PMDA may grant priority review to drugs that treat serious conditions with medical need and show significant clinical improvement. Priority review targets 9 months total review time.

Re-examination and Re-evaluation Systems

Japan has unique post-approval monitoring systems that do not exist in the same form in other ICH regions.

Re-examination (Saishinsasedo)

After marketing approval, new drugs are subject to a re-examination period during which the MAH must collect post-market data and submit a re-examination report.

During the re-examination period:

• The MAH must conduct use-results surveys (a form of post-marketing surveillance)
• Case numbers and reporting requirements are specified at the time of approval
• At the end of the period, the MAH submits all collected data for PMDA's re-examination
• PMDA assesses whether the benefit-risk profile remains favorable

The re-examination period also functions as a form of data protection. Generic applications cannot reference the innovator's data during this period.

Re-evaluation (Saihyokasedo)

MHLW can order a re-evaluation of any approved drug if new safety information emerges or if the benefit-risk balance may have changed. This is distinct from the routine re-examination and can occur at any time.

GMP Requirements in Japan

J-GMP Standards

Japanese GMP (J-GMP) is based on the Ministerial Ordinance on Standards for Manufacturing Control and Quality Control (GMP Ordinance). While broadly aligned with PIC/S GMP (Japan became a PIC/S member in 2014), J-GMP has some Japan-specific requirements:

Foreign Site Inspections

PMDA conducts on-site GMP inspections of foreign manufacturing facilities. Key points:

• Pre-approval inspections are conducted for new drug applications
• Routine inspections occur every 5 years (aligned with GMP certificate validity)
• PMDA inspectors travel to the foreign site
• Inspections follow J-GMP standards, which may differ in emphasis from FDA or EMA inspections
• Language interpretation must be arranged by the applicant/MAH

Mutual Recognition

Japan has entered into MRA arrangements with several countries for GMP inspections, including EU member states through the Japan-EU MRA. This allows partial reliance on partner authority inspection findings, but PMDA retains the right to conduct its own inspections.

Practical Considerations for Sponsors

Timeline Planning for Japan Filing

For sponsors developing drugs globally as part of a global regulatory strategy, Japan filing strategy must account for:

1. Bridging study planning: Discuss with PMDA early (Clinical Data Package Consultation) to determine if a bridging study is needed and what design is acceptable
2. Language: All Module 1 in Japanese; budget time and cost for translation
3. MAH requirement: Must have a legal entity in Japan
4. GMP inspection lead time: PMDA foreign site inspections require advance scheduling
5. NHI pricing: Budget for a separate post-approval reimbursement and price-listing process before commercial launch
6. Consultation fees: Budget for PMDA consultation fees at each development stage

Common Pitfalls

Key Regulatory References

• Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act)
• Ministerial Ordinance on Standards for Manufacturing Control and Quality Control (GMP Ordinance)
• ICH E5: Ethnic Factors in the Acceptability of Foreign Clinical Data
• PMDA Guidance: Preparation of CTD for New Drug Applications
• PMDA Guidance: eCTD Specifications for Electronic Submissions
• Japanese Pharmacopoeia, 18th Edition (JP18)
• MHLW Notification on SAKIGAKE Designation System
• MHLW Notification on Conditional Early Approval System

This guide reflects the Japanese drug regulatory framework as of early 2026. The PMD Act and implementing regulations are periodically revised. Always verify current requirements with PMDA and MHLW official publications before filing.

References